Study drug for mild to moderate Alzheimer's disease
Part of Brain & nervous system, Mental health clinical trials.
This trial tests a new drug, NBI-1117567, for people with mild to moderate Alzheimer's disease who are already taking a standard Alzheimer's medication. The goal is to see if the new drug can help improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with mild to moderate Alzheimer's disease.
- You are currently taking donepezil, galantamine, or rivastigmine for at least 3 months and can keep taking it during the study.
- You are not pregnant or planning to become pregnant during the study.
- You do not have other conditions that could cause memory loss, such as Parkinson's disease or a history of head injury.
- You are willing to follow study procedures and attend study visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, VHB937, in people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow down memory loss and thinking problems.
This trial tests an investigational injection for people in the early stages of Alzheimer's. It aims to see if the drug can safely slow down memory loss and brain changes.
This trial tests a new treatment called NMS-01 for people with mild to moderate Alzheimer's disease. It aims to see if it's safe and may help with symptoms.
This study tests an experimental drug called RO7568282 for people in the early stages of Alzheimer's disease. The goal is to see if it is safe and whether it can slow down memory loss and thinking problems.
This trial tests an investigational drug called ALN-5288 for people with Alzheimer's disease. It aims to see if the drug is safe and how it affects the body.
This early-stage trial tests whether ABBV-1758, a new drug given by injection, is safe and effective for people with Alzheimer's disease. The drug targets amyloid, a protein that builds up in the brains of people with Alzheimer's.
Hear when a new Alzheimer’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.